NDA 018140 · Hikma
Ativan
Lorazepam · Injection · Benzodiazepine
Last checked: Nov 19, 2026Latest source record: Jan 13, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1980
Jul 25, 1980
Approved uses
2
Original approval plus efficacy supplements
Registered trials
157
26 Phase 3, 11 recruiting
FAERS reports
180,741
139,049 serious, 26,091 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: RISKS FROM CONCOMITANT USE WITH OPIOIDS; ABUSE, MISUSE, AND ADDICTION; and DEPENDENCE AND WITHDRAWAL REACTIONS Concomitant use of benzodiazepines and opioids may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing of these drugs in patients for whom alternative treatment options are inadequate. Limit dosages and durations to the minimum required. Follow patients for signs and symptoms of respiratory depression and sedation (see WARNINGS and PRECAUTIONS ). The use of benzodiazepines, including Lorazepam Injection, exposes users to risks of abuse, misuse, and addiction, which can lead to overdose or death. Abuse and misuse of benzodiazepines commonly involve concomitant use of other medications, alcohol, and/or illicit substances, which is associated with an increased frequency of serious adverse outcomes. Before prescribing...
What it is approved for
From the label in effect Nov 9, 2026.
INDICATIONS AND USAGE Status Epilepticus Lorazepam Injection is indicated for the treatment of status epilepticus. Preanesthetic Lorazepam Injection is indicated in adult patients for preanesthetic medication, producing sedation (sleepiness or drowsiness), relief of anxiety, and a decreased ability to recall events related to the day of surgery. It is most useful in those patients who are anxious about their surgical procedure and who would prefer to have diminished recall of the events of the day of surgery (see PRECAUTIONS, Information for Patients ).
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Sep 5, 1997 Supplement 3 · Efficacy Review
- Jul 25, 1980 Original approval · Type 3 - New Dosage Form
2 products under this application
- ATIVAN · LORAZEPAM 4MG/ML · INJECTABLE, INJECTION · Prescription · TE AP
- ATIVAN · LORAZEPAM 2MG/ML · INJECTABLE, INJECTION · Prescription · TE AP
Clinical trials
Interventional ClinicalTrials.gov studies with "Lorazepam" as an intervention, any sponsor and status, largest first.
- Sedative Premedication: Efficacy On Patient ExperiencePivotal-lookingCompleted
Assistance Publique Hopitaux De MarseilleAcademic, hospital or other
NCT01901003 · 1,200 participants · Start Nov 2012 · Primary completion Jun 2014
Drug: Lorazepam; Placebo (microcrystalline celluloses) · For: Perioperative Anxiety
Sites: Marseille, France
- Paramedic Treatment of Prolonged Seizures by Intramuscular Versus Intravenous Anticonvulsant MedicationsPivotal-lookingCompleted
Robert SilbergleitAcademic, hospital or other
NCT00809146 · 1,023 participants · Start Jun 2009 · Primary completion Jan 2011
Drug: Intramuscular route of active treatment; Intravenous route of active treatment · For: Status Epilepticus
Sites: Tucson, Arizona; Palo Alto, California; San Francisco, California · 17 sites in all
- Randomized Trial Comparing 3 Routes of Delivering Lorazepam to Children.Pivotal-lookingTerminated
Kamuzu University of Health SciencesAcademic, hospital or other
NCT00343096 · 800 participants · Start Jun 2006 · Primary completion Mar 2009
Drug: Lorazepam · For: Status Epilepticus; Convulsions
Sites: Blantyre, Malawi
- Biological Basis of Individual Variation in Social CooperationPivotal-lookingCompleted
Emory UniversityAcademic, hospital or other
NCT01566539 · 707 participants · Start Apr 2008 · Primary completion Nov 2016
Drug: Intranasal Oxytocin (OT) 24 IU; Intranasal Vasopressin (AVP) and 3 more · For: Healthy
Sites: Atlanta, Georgia · 2 sites in all
- Safety and Efficacy Evaluation Of Pregabalin (Lyrica) With Patients With Generalized Anxiety DisorderPivotal-lookingCompleted
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.Pfizer (PFE)
NCT00624780 · 615 participants · Start May 2009 · Primary completion Apr 2012
Drug: Pregabalin; Lorazepam and 2 more · For: Generalized Anxiety Disorder
Sites: La Plata, Argentina; Lanus, Argentina; Buenos Aires, Argentina · 57 sites in all
- EDG004 Treatment of Adult Patients With Generalized Anxiety Disorder (GAD)Pivotal-lookingCompleted
Edgemont Pharmaceuticals, LLCIndustry
NCT02305797 · 495 participants · Start Jan 2015 · Primary completion May 2016
Drug: Extended-release lorazepam; Placebo · For: Generalized Anxiety Disorder (GAD)
Sites: Multiple Locations, California
- Benzodiazepine-free Anesthetic for Reduction of Delirium (B-Free)Pivotal-lookingCompleted
McMaster UniversityAcademic, hospital or other
NCT03053869 · 480 participants · Start Apr 1, 2017 · Primary completion Sep 30, 2018
Drug: Benzodiazepine - limited use strategy; Benzodiazepine - Ad libitum strategy · For: Post-operative Delirium
Sites: Winnipeg, Canada; Hamilton, Canada
- Comparison Between Lorazepam, Clonazepam and Clonazepam + Fosphenytoin for the Treatment of Out-of-hospital Generalized Status EpilepticusPivotal-lookingCompleted
Assistance Publique - Hôpitaux de ParisAcademic, hospital or other
NCT01870024 · 434 participants · Start Jun 26, 2013 · Primary completion Feb 23, 2018
Drug: Clonazepam; Fosphenytoin and 2 more · For: Status Epilepticus; Epilepsy
Sites: Paris, France
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- fatigue13,956
- nausea13,776
- drug ineffective12,685
- diarrhoea10,751
- off label use10,745
- dyspnoea9,576
- anxiety9,118
- headache8,993
- pain8,962
- vomiting8,920
- dizziness8,419
- asthenia7,347
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 3,054 |
| 2005 | 3,435 |
| 2006 | 3,344 |
| 2007 | 3,141 |
| 2008 | 3,345 |
| 2009 | 4,196 |
| 2010 | 5,682 |
| 2011 | 6,022 |
| 2012 | 7,365 |
| 2013 | 5,867 |
| 2014 | 6,989 |
| 2015 | 10,425 |
| 2016 | 11,232 |
| 2017 | 11,734 |
| 2018 | 13,417 |
| 2019 | 13,188 |
| 2020 | 12,712 |
| 2021 | 11,112 |
| 2022 | 10,402 |
| 2023 | 9,527 |
| 2024 | 9,573 |
| 2025 | 8,976 |
| 2026 | 5,997 |
Recalls
6 FDA enforcement reports for this application.
Jul 22, 2025 · Class II · Ongoing
Failed Impurities/Degradation Specifications: An out-of-Specification for total related compounds
May 11, 2023 · Class II · Terminated
Failed Impurities/Degradation Specifications: Out-of-specification results for total related compounds observed during retain steting due to the elevated Related Compound-C.
Jul 11, 2022 · Class II · Terminated
Failed Impurities/Degradation Specifications: Out-of-specification results observed for total related compounds during testing of retain samples.
Jul 11, 2022 · Class II · Terminated
Failed Impurities/Degradation Specifications: Out-of-specification results observed for total related compounds during testing of retain samples.
Jul 11, 2022 · Class II · Terminated
Failed Impurities/Degradation Specifications: Out-of-specification results observed for total related compounds during testing of retain samples.
Jul 11, 2022 · Class II · Terminated
Failed Impurities/Degradation Specifications: Out-of-specification results observed for total related compounds during testing of retain samples.
Shortages
FDA's drug shortage list.
Current · updated Oct 14, 2026
Lorazepam, Injection, 4 mg/1 mL (NDC 0641-6045-25). Demand increase for the drug
Current · updated Oct 14, 2026
Ativan, Injection, 2 mg/1 mL (NDC 0641-6001-25). Demand increase for the drug
Current · updated Oct 14, 2026
Ativan, Injection, 2 mg/1 mL (NDC 0641-6000-10). Other
Current · updated Oct 14, 2026
Ativan, Injection, 4 mg/1 mL (NDC 0641-6003-25). Demand increase for the drug
Current · updated Oct 14, 2026
Lorazepam, Injection, 2 mg/1 mL (NDC 0641-6044-25). Demand increase for the drug
Current · updated Oct 14, 2026
Ativan, Injection, 4 mg/1 mL (NDC 0641-6002-10). Other
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Ativan* (Lorazepam)
2024 spending
$22.6M
Beneficiaries
1,633
6,598 claims
Per beneficiary
$13,820
$40.05 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $22,372,746 |
| 2021 | $23,741,088 |
| 2022 | $24,316,631 |
| 2023 | $24,289,925 |
| 2024 | $22,568,403 |
Part B: Ativan* (Lorazepam*) · HCPCS J2060
2024 spending
$13K
Beneficiaries
3,752
9,674 claims
Per beneficiary
$3
2024 ASP limit $1.21 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $19,411 |
| 2021 | $16,206 |
| 2022 | $13,456 |
| 2023 | $17,316 |
| 2024 | $12,588 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Proportional Sedation for Persistent Agitated Delirium in Palliative Care: A Randomized Clinical Trial.
Hui D, De La Rosa A, Tsai JS, et al. · JAMA Oncol 2025 · Multicenter Study, Randomized Controlled Trial
- Phenobarbital for acute alcohol withdrawal: a prospective randomized double-blind placebo-controlled study.
Rosenson J, Clements C, Simon B, et al. · J Emerg Med 2013 · Randomized Controlled Trial
- Intramuscular versus intravenous therapy for prehospital status epilepticus.
Silbergleit R, Durkalski V, Lowenstein D, et al. · N Engl J Med 2012 · Clinical Trial, Phase III, Comparative Study
- GABAergic Involvement in Selective Attention.
Faßbender K, Baumert PM, Wintergerst MWM, et al. · J Cogn Neurosci 2023 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Benzodiazepines for delirium.
Lonergan E, Luxenberg J, Areosa Sastre A, et al. · Cochrane Database Syst Rev 2009 · Systematic Review
- Benzodiazepines for delirium.
Lonergan E, Luxenberg J, Areosa Sastre A · Cochrane Database Syst Rev 2009 · Systematic Review
Sponsor: Hikma
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.